New research from the University of Illinois highlights how mutations in yeast linked to canine ear infections are driving resistance to commonly used antifungal treatments, underscoring the need for careful drug stewardship in veterinary practice.
Veterinarians are increasingly encountering cases of recurrent fungal otitis externa in dogs that fail to respond to standard topical azoles such as miconazole. A study led by Professor Lois Hoyer and Dr. Clarissa Pimentel de Souza analyzed yeast samples from affected dogs, focusing on the ERG11 gene, which encodes the Erg11 protein targeted by azole antifungals. The team discovered that specific amino acid substitutions in Erg11 altered the protein’s structure, preventing effective binding of miconazole and reducing drug efficacy. Importantly, resistant strains showed improved response to posaconazole, a longer-tailed azole with more binding contact points, though researchers caution against indiscriminate use of stronger antifungals.
Dr. Souza emphasized that recurrent infections often stem from underlying allergic conditions that remain untreated. Reliance on repeated antifungal courses without addressing primary allergic disease fosters chronic drug exposure and increases the risk of resistance. The study recommends a tiered therapeutic approach: short-tailed azoles such as miconazole or clotrimazole should remain first-line treatments, while medium- and long-tailed azoles like ketoconazole and posaconazole should be reserved for cases that are recurrent or nonresponsive. This strategy aims to preserve the effectiveness of available antifungal agents and reduce the likelihood of resistance development.
The research also classified yeast isolates into three phylogenetic groups, linking genetic variations to drug susceptibility patterns. Collaborations with structural biologists confirmed how protein changes impact drug binding, providing a molecular basis for clinical resistance. Future work will expand testing across multiple antifungal agents and correlate DNA sequence changes with treatment outcomes, further guiding stewardship practices.
For veterinary professionals, the findings reinforce the importance of diagnosing and managing underlying allergic conditions alongside antifungal therapy, tailoring drug choice to clinical response, and avoiding broad-spectrum or “all-in-one” antifungal use unless clearly indicated. With antifungal resistance emerging as a significant challenge in small animal dermatology and otology, judicious prescribing and stewardship are essential to safeguard treatment efficacy.
AUTHOR PROFILE
Innovative Veterinary Care Journal bridges the gap between the worlds of allopathic and integrative veterinary care. Thousands of veterinarians and vet technicians are interested in ways to enhance their practice and update their skills…and integrative health is considered to be highly innovative and requested by patients along with a vast number of other traditional and emerging techniques. IVC features articles by some of the top experts, focusing on market trends in health treatments, new product features, industry news, how to create a strong retail experience, leading integrative modalities, and nutrition education not typically taught in vet school.
